Notably, analyzing scRNA-seq data from BRCA patients receiving anti-PD-1 immunotherapy, we have identified that anti-PD-1 immunotherapy enhances the capacity of iCAFs to promote the establishment of an immunosuppressive microenvironment. The gene discussed is PDCD1; the disease is invasive breast carcinoma.